about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

FDA ex­pands la­bel for Vi­iV's Cabe­nu­va to cov­er bi-month­ly ad­min­is­tra­tion HIV treat­ment

4 years ago
Pharma

Take­da spins PhII rare dis­ease pro­grams in­to new start­up — send­ing 2 ex­ecs and some cash to get things go­ing

4 years ago
Startups

'Thor­ough­ly f*****d' for cy­ber­at­tacks?; Bad week for drug de­vel­op­ers; The next big I/O break­through?; Bio­gen does a ...

4 years ago
Weekly

Un­der the gun with Aduhelm floun­der­ing, Bio­gen sells its stake in biosim­i­lars busi­ness for $2.3B

4 years ago
Deals

Covid-19 roundup: Mod­er­na kicks off tri­al for Omi­cron-spe­cif­ic vac­cine; EMA signs off on Pfiz­er pill

4 years ago
Coronavirus

Sell­ing shares at a dis­count, Zymeworks grabs $100M cash in hopes of turn­around

4 years ago
Financing

Days af­ter Gilead yanks PI3K drug, In­cyte with­draws NDA for its own PI3K — say­ing con­fir­ma­to­ry tri­als would take ...

4 years ago
FDA+

Small biotechs with big drug am­bi­tions threat­en to up­end the tra­di­tion­al drug launch play­book

4 years ago
In Focus
Marketing

Sur­prise piv­ot rocks eF­FEC­TOR's I/O plans — al­though ex­ecs promise big­ger slice of the NSCLC mar­ket in the long run

4 years ago
R&D

Nasal sprays to stave off virus­es days at a time? J&J’s newest biotech part­ner draws $140M for 'proac­tive' ap­proach

4 years ago
Financing

Months af­ter pulling on­ly drug from US, On­copep­tides takes back with­draw­al re­quest — but stays mum on why

4 years ago
FDA+
Marketing

What lured Hal Bar­ron away?; Top FDA minds on ac­cel­er­at­ed ap­proval re­forms; ‘Dead wrong’ Aduhelm ad blitz; and ...

4 years ago
Weekly

Faced with in­tense in­vestor back­lash, Unilever now says $68B is its fi­nal of­fer for GSK con­sumer health­care busi­ness

4 years ago
Deals

As­traZeneca rolls out 'un­prece­dent­ed' 3-year sur­vival da­ta for PD-L1/CT­LA4 com­bo in liv­er can­cer

4 years ago
R&D
Pharma

UCB buys its way to epilep­sy show­down with Jazz with $1.9B Zo­genix ac­qui­si­tion

4 years ago
Deals

Hal Bar­ron keeps 23andMe close on GSK's side to find more genes the R&D team can go af­ter

4 years ago
Deals

Ready for an M&A fight? Af­ter GSK shunned $68B of­fer, Unilever says it's still in hunt for con­sumer health JV

4 years ago
Deals
Pharma

Lat­est news on Pfiz­er's $3B+ JAK1 win; Pacts over M&A at #JPM22; 2021 by the num­bers; Bio­gen's Aduhelm reck­on­ing; The ...

4 years ago
Weekly

Three years, a clin­i­cal hold and a death lat­er, Sarep­ta aban­dons part­nered piv­otal-stage gene ther­a­py

4 years ago
Deals
Cell/Gene Tx

Sanofi joins the al­pha-synu­cle­in band­wag­on, hand­ing Ko­re­an biotech $75M for pre­clin­i­cal bis­pe­cif­ic

4 years ago
Deals

Reel­ing from FDA re­jec­tion, Be­yond­Spring ax­es 35% of US staffers in hopes of I/O come­back

4 years ago
People
China

Bob Nelsen, Anne Wo­j­ci­c­ki join $20M round for longevi­ty start­up hop­ing to slow down ag­ing of the ovary

4 years ago
Financing
Startups

Sarep­ta's sec­ond shot at show­ing its Duchenne gene ther­a­py de­liv­ers pos­i­tive da­ta but un­der­whelms — shares tum­ble

4 years ago
R&D
Cell/Gene Tx

Bris­tol My­ers to spend $50B on deals, buy­backs in next 3 years — al­though BD chief notes find­ing the right deal ...

4 years ago
Deals
First page Previous page 38394041424344 Next page Last page
A service from the Financial Times